Publications | Lund University Publications

1 – 8 of 8

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22Bj%C3%B8ro%2C+Kristian%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22Bj%C3%B8ro%2C+Kristian%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2015
Mark The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
Dalgard, Olav ; Martinot-Peignoux, Michelle ; Verbaan, Hans ^LU ; Bjøro, Kristian ; Ring-Larsen, Helmer and Marcellin, Patrick (2015) In PLoS ONE 10(8).
- Contribution to journal › Article
2012
Mark Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Eskesen, Arne Nørgaard ; Melum, Espen ; Moghaddam, Amir ; Bjøro, Kristian ; Verbaan, Hans ^LU ; Ring-Larsen, Helmer and Dalgard, Olav (2012) In European Journal of Gastroenterology and Hepathology 24(8). p.890-896
- Contribution to journal › Article
2011
Mark IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection
Moghaddam, Amir ; Melum, Espen ; Reinton, Nils ; Ring-Larsen, Helmer ; Verbaan, Hans ^LU ; Bjoro, Kristian and Dalgard, Olav (2011) In Hepatology 53(3). p.746-754
- Contribution to journal › Article
2010
Mark In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
Dalgard, Olav ; Bjoro, Kristian ; Ring-Larsen, Helmer and Verbaan, Hans ^LU (2010) In European Journal of Gastroenterology and Hepathology 22. p.552-556
- Contribution to journal › Article
Mark Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection
Dalgard, Olav ; Moghaddam, Amir ; Verbaan, Hans ^LU ; Ring-Larsen, Helmer ; Bjoro, Kristian and Melum, Espen (2010) 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 52(4). p.898-898
- Contribution to journal › Published meeting abstract
2009
Mark Low-To-Moderate Alcohol Consumption has no Impact on Antiviral Response to Combination Therapy In Hcv Patients with Genotype 2 or 3
Carvalho-Filho, Roberto J. ; Verbaan, Hans ^LU ; Bjoro, Kristian ; Ring-Larsen, Helmer and Dalgard, Olav (2009) 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 50(4). p.819-819
- Contribution to journal › Published meeting abstract
2008
Mark IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS
Dalgard, Olav ; Verbaan, Hans ^LU ; Ring-Larsen, Helmer and Bjoro, Kristian (2008) 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 48(4). p.1875-1875
- Contribution to journal › Published meeting abstract
Mark Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Dalgard, Olav ; Bjoro, Kristian ; Ring-Larsen, Helmer ; Bjornsson, Einar ; Holberg-Petersen, Mona ; Skovlund, Eva ; Reichard, Olle ; Myrvang, Bjorn ; Sundelof, Bo and Ritland, Stale , et al. (2008) In Hepatology 47(1). p.35-42
- Contribution to journal › Article